Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative
| Press Release | ||
| Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative | ||
June 6, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, reminds its shareholders that the Ordinary and Extraordinary General Meeting will be held on Friday, June 27, 2025 at 2:30 p.m., at the Company’s headquarters located at Sundesk Sophia Antipolis, rue Evariste Galois, Emerald Square, Bâtiment C – 06410 Biot. The agenda and the text of the draft resolutions proposed to the Ordinary and Extraordinary Shareholders’ Meeting are included in the notice of meeting published in the Bulletin des Annonces Légales Obligatoires (Official Bulletin of Mandatory Legal Announcements) No. 61 dated May 21, 2025 (No. 2502198) and No. 64 dated May 28, 2025 ( No. 2501651). Appointment of an Ad Hoc Representative to Represent Defaulting Shareholders In light of the significant difficulties in reaching the required quorum, the President of the Antibes Commercial Court, has appointed by order on May 6, 2025, SCP EZAVIN-THOMAS, represented in the person of Maître Nathalie Thomas, domiciled 1, Alexandre Mari – 06000 Nice, as ad hoc representative to represent defaulting shareholders at the Ordinary and Extraordinary Shareholder’s Meeting convened for June 27, 2025 on first call. The ad hoc representative will thus represent all the shares with voting rights held by shareholders who have not participated or are not represented at this General Meeting. The participation of the ad hoc representative will thus bring the quorum to 100% of shares with voting rights. In order to ensure the neutrality of the ad hoc representative’s role, the voting rights attached to the shares of the defaulting shareholders will be exercised as follows:
The documents relating to the General Meeting, including the text of the draft resolutions and the proxy form, are made available to shareholders at the Company’s headquarters and on its website (). Shareholders may vote by proxy, by internet or by attending the Ordinary and Extraordinary Shareholder Meeting in person. A guide explaining how to vote, and notably how to vote by internet, is available on the Company’s website. Shareholders may also contact the Company’s Investor Relations team at for any questions regarding the voting process. | ||
| About Nicox | ||
| Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information | ||
| Analyst coverage | ||
H.C. Wainwright & Co Yi Chen New York, U.S. | ||
| The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. | ||
| Contacts | ||
| Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 | ||
| Disclaimer | ||
| The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. | ||
| Nicox S.A. Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00 | ||
Attachment
